Related Experiment Videos
Thalidomide: dual benefits in palliative medicine and oncology
1Harry R. Horvitz Center for Palliative Medicine (a World Health Organization Demonstration Project), Cleveland, Ohio, USA.
The American Journal of Hospice & Palliative Care
|September 22, 2001
Abstract:
Thalidomide is an immunomodulator, anti-angiogenic agent, anti-cytokine, and anti-integrin. Alone or in combination with other drugs, thalidomide has also demonstrated anti-cachexin and anti-neoplastic properties. Anorexia and cachexia are common symptoms of advanced cancer. Since certain cytokines also promote tumor growth, we may have a class of agents with palliative and anti-tumor benefits in combination with anti-neoplastics and anti-cytokines, such as thalidomide.